Datavant and Indegene Partner to Accelerate Clinical Trial Recruitment for Rare Diseases
核心洞察
Datavant (搜索) and Indegene (搜索) have formed a strategic partnership to enhance patient recruitment for clinical trials, particularly focusing on rare disease and complex studies.
The collaboration integrates Datavant (搜索)'s data enrichment capabilities into Indegene (搜索)'s NEXT Patient Recruitment platform, leveraging a network of over 80,000 hospitals and clinics processing 100 million patient records annually.
The partnership aims to reduce screen failures, accelerate enrollment timelines, and improve screen-to-randomization ratios for biopharmaceutical organizations.
US-based Datavant (搜索), a healthcare data collaboration platform, has announced a strategic partnership with Bengaluru-based Indegene (搜索), a digital-first life sciences commercialization company, to enhance patient recruitment for clinical trials with a particular focus on rare disease and complex studies. The collaboration embeds Datavant's data enrichment capabilities into Indegene's NEXT Patient Recruitment platform, promising faster trial enrollment, reduced screen failures, and more efficient recruitment processes for biopharmaceutical organizations.
Addressing Critical Recruitment Challenges
Patient recruitment represents one of the most significant obstacles in clinical development, with the challenge becoming particularly acute in rare diseases (搜索) where eligible populations are both small and geographically dispersed. Datavant (搜索) operates the nation's largest health data retrieval network, spanning more than 80,000 hospitals and clinics while processing over 100 million patient records annually.
The partnership combines this extensive data infrastructure with Indegene (搜索)'s digitally powered clinical trial recruitment solutions to streamline the identification of suitable study participants based on specific health data criteria. This integration enables more eligible participants to connect with trials designed for their specific health conditions, including patients with rare and complex diseases.
Enhanced Screening and Enrollment Capabilities
The collaboration enables biopharmaceutical companies to reduce site-level screen failures, accelerate enrollment timelines, improve screen-to-randomization ratios, and drive more informed decision-making. By integrating secure, real-time access to consented patient medical records into the screening process, the partnership addresses one of clinical trials' greatest challenges - screen failures at sites due to incomplete and ineffective pre-screening.
"Rare diseases (搜索) have long been defined by the impossibility of finding enough patients fast enough to bring new therapies to market," said Arnaub Chatterjee, President and GM of Life Sciences at Datavant (搜索). "Together with Indegene (搜索), we are demonstrating how data enrichment solves that challenge today - and lays the foundation for a new model of clinical research in which sponsors can accelerate recruitment across even the most complex and hard-to-reach populations."
Strategic Positioning and Market Impact
Ram Yeleswarapu, SVP of Enterprise Clinical Solutions at Indegene (搜索), emphasized the partnership's role in the company's digital transformation strategy. "We are doubling down on enhancing our capabilities to deliver digital-first recruitment solutions for clients to transform clinical trial execution. Our partnership with Datavant (搜索) is a key step in this journey," he stated. "This collaboration reinforces our positioning as the industry's premier digital-first recruitment partner, empowering sponsors and sites with data-driven approaches that deliver measurable outcomes."
The partnership represents a significant development in addressing the persistent challenge of patient recruitment in clinical trials, particularly for rare diseases (搜索) where traditional recruitment methods often fall short due to limited patient populations and geographic constraints.